Chengdu Okay Pharmaceutical Co (BJSE:920230) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920230 Chengdu Okay Pharmaceutical Co Ltd BJSE:920230
73 GF Score
Price ¥11.64
GF Value ¥11.12
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Chengdu Okay Pharmaceutical Co LT-Debt-to-Total-Asset?

Chengdu Okay Pharmaceutical Co BJSE:920230 73 LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026. GuruFocus rates BJSE:920230 with a GF Score™ of 73/100 and a GF Value™ of ¥11.12 (Fairly Valued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Chengdu Okay Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.00.

Chengdu Okay Pharmaceutical Co's long-term debt to total assets ratio stayed the same from Jun. 2025 (0.00) to Jun. 2026 (0.00).

Chengdu Okay Pharmaceutical Co  (BJSE:920230) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Chengdu Okay Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Chengdu Okay Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Chengdu Okay Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Okay Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Chengdu Okay Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chengdu Okay Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BJSE:920230
73GF Score
Chengdu Okay Pharmaceutical Co Ltd BJSE:920230
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Okay Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Chengdu Okay Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.486/531.583
=0.00

Chengdu Okay Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=0.38/514.49
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Chengdu Okay Pharmaceutical Co (BJSE:920230) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Chengdu Okay Pharmaceutical Co and its competitors.
Is Chengdu Okay Pharmaceutical Co's LT-Debt-to-Total-Asset too high?
Chengdu Okay Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Chengdu Okay Pharmaceutical Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Okay Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS?
Chengdu Okay Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Chengdu Okay Pharmaceutical Co and its competitors. Chengdu Okay Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Okay Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co (BJSE:920230) is currently considered Fairly Valued. The stock's GF Value™ is ¥11.12, compared to a current price of ¥11.64 — trading 4.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Chengdu Okay Pharmaceutical Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Chengdu Okay Pharmaceutical Co (BJSE:920230), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Okay Pharmaceutical Co (BJSE:920230) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥11.64 is trading 4.7% above its estimated GF Value™ of ¥11.12. GuruFocus considers Chengdu Okay Pharmaceutical Co to be Fairly Valued.

Key valuation signals for BJSE:920230:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: ¥11.12 vs. price of ¥11.64 (4.7% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the BJSE:920230 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Okay Pharmaceutical Co Business Description

Address No. 15 Chuangye Road,, Linqiong Industrial Park, Sichuan Province, Qionglai City, CHN, 611530
Chengdu Okay Pharmaceutical Co Ltd engages in research and development, production, and sales of plant extracts. It specializes in natural vitamin P products, including large-scale professional planting, extraction, purification, synthesis, and application. Its product series include Citrus Extract Series, Sophorae Japonica Series, and Miscellaneous Extract Series.
73GF Score

Get the complete analysis for BJSE:920230

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.64
Price
¥11.12
GF Value